Scientific deep-dive

Bimagrumab Plus Semaglutide: The Muscle Question

The combination lost 17.8 kg at 48 weeks against 14.2 kg for semaglutide alone. But bimagrumab exists to change what you lose, and the published summary reports only how much.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

If the objection to GLP-1 drugs is that they take muscle along with fat, the obvious answer is a second drug that protects muscle. Bimagrumab is that drug, and a 2026 phase 2 trial tested it alone, with semaglutide, and against placebo in 507 adults. The combination lost 17.8 kg at 48 weeks against 14.2 kg for semaglutide alone.[1] What the published summary does not report is the number the whole idea rests on.

What the trial found

Adults were eligible with obesity, or with overweight plus at least one obesity-associated complication. They were randomized across nine groups for 48 weeks, followed by an open-label extension to week 72. Bimagrumab is given intravenously every 12 weeks; it targets type II activin receptors, with the intent of reducing fat mass while promoting muscle growth.[1]

Least-squares mean absolute change in body weight at week 48. All groups shown differ from placebo at p<0.001.
GroupWeight change
Placebo−3.3 kg
Bimagrumab 30 mg/kg−9.3 kg
Semaglutide 2.4 mg−14.2 kg
Bimagrumab 30 mg/kg + semaglutide 2.4 mg−17.8 kg

Improvements continued through week 72. Bimagrumab’s common adverse events were muscle spasms, diarrhea and acne; semaglutide brought the familiar nausea, diarrhea, constipation and fatigue.[1]

The number that is missing

Bimagrumab’s entire rationale is composition: not how much weight comes off, but what kind of tissue it is. The published summary reports total body weight and does not report the fat-versus-lean split.

A drug designed to change what you lose, reported by how much you lose. The headline figure is not the one the hypothesis is about.

So the trial shows less than the excitement around this combination suggests. It establishes that adding bimagrumab produces more weight loss than semaglutide alone. It does not, in what has been published here, establish that the weight lost was more favorably composed, and that is the claim the drug exists to make. If you see this trial cited as proof that muscle was preserved, check whether the person citing it has a body-composition number or is assuming one.

This matters beyond one trial. Our piece on muscle volume versus muscle function found lean mass falling 9.3% while physical performance edged up. Even a real composition benefit would still need to show that it changes what someone can do. Mass is the easy measurement; function is the point.

What this is and is not, practically

  • Phase 2, not phase 3. 507 people across nine arms means each arm is small, and phase 2 results routinely shrink when tested properly.
  • An intravenous infusion every 12 weeks. This is not a pen you take home. It changes cost, access and who realistically receives it.
  • Not available, and not close. Nobody can prescribe this combination outside a trial, and no compounder can lawfully supply it (see what cannot legally be compounded).
  • New adverse events, not just more of the old ones. Muscle spasms and acne are bimagrumab’s, not semaglutide’s.

The direction is interesting. Combination therapy aimed at composition rather than scale weight is where obesity medicine is going, and bimagrumab is not the only candidate: apitegromab has been tested alongside tirzepatide. This is a real trial, and the result is a real one. It is also a phase 2 result, and a phase 3 program would have to confirm it before it means anything to a reader.

Frequently Asked Questions

That is the hypothesis, and the published summary of this trial does not report the fat-versus-lean split needed to confirm it. What it reports is total weight: 17.8 kg lost on the combination against 14.2 kg on semaglutide alone. Treat any claim that muscle was preserved as needing a number that this summary does not provide.
At 48 weeks, the high-dose combination lost 17.8 kg against 14.2 kg for semaglutide 2.4 mg alone, 9.3 kg for bimagrumab alone and 3.3 kg for placebo. Improvements continued through a week-72 extension.
No. It is a phase 2 trial result, bimagrumab is not approved, and it comes as an intravenous infusion every 12 weeks rather than as a pen. No compounder can lawfully supply it either.
Bimagrumab's common adverse events in this trial were muscle spasms, diarrhea and acne, a different set from semaglutide's nausea, diarrhea, constipation and fatigue. Adding a drug adds its own profile rather than simply amplifying the first.
It is clearly the direction of research, and aiming at body composition rather than scale weight is a more sophisticated target than the field has used so far. Phase 2 results routinely shrink in phase 3, so the reasonable stance is interest rather than expectation.

References

  1. 1.Heymsfield SB, Aronne LJ, Montgomery P, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial Nature Medicine. 2026. PMID: 41772149.

A Drug to Protect Muscle

A myostatin-targeting antibody tested alongside tirzepatide was well tolerated and, the authors conclude, effective at preserving lean mass. In its one trial, people on it lost 1.9 kg less lean mass than on placebo.

5 min read

CagriSema Beat Semaglutide. By How Much?

CagriSema was statistically superior to semaglutide on HbA1c in type 2 diabetes. The margin was 0.16 percentage points, and adverse events were higher: 86.9% against 81.2%.

5 min read

MariTide (Maridebart Cafraglutide): What the Evidence Shows

Amgen's monthly MariTide cut weight 12.3% to 16.2% at 52 weeks in phase 2, against 2.5% on placebo. It blocks GIP where tirzepatide activates it. Side effects, the MARITIME phase 3 trials, and why it cannot be bought yet.

10 min read

Cagrilintide: What the Evidence Shows, and Why You Can't Buy It

Cagrilintide, Novo Nordisk's amylin analog, produced 11.8% weight loss on its own at 68 weeks, less than semaglutide. It is not approved, cannot be compounded, and FDA has warned companies selling it.

9 min read

Elecoglipron: A Second Oral GLP-1 Pill in Phase 2

Weight reductions from 2.6% to 10.5% at 26 weeks depending on dose, against 0.6% on placebo. 93% completed the study but only 75% completed the assigned treatment.

5 min read

Eloralintide and Petrelintide: The Amylin-Only Drugs in Phase 3

In phase 2, Lilly's eloralintide cut weight by about 20% at 48 weeks; Zealand and Roche's petrelintide up to 10.7% at 42 weeks with little vomiting. Both are in phase 3, due to finish in 2028. Neither is approved.

10 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.1

Direct Meds

8.2

bmiMD

Starting below a standard dose, with microdose tiers

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →